JAZZ - Jazz Pharmaceuticals plc
NEXT EARNINGS:
May 4, 2026
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$205.14
DETAILS
HIGH:
$235.00
LOW:
$170.00
MEDIAN:
$205.00
CONSENSUS:
$205.14
UPSIDE:
18.01%
Market Cap:
10.56B
Volume:
970,769
Avg Volume:
991,286
52 Week Range:
95.49-182.99
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.25
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
IE
Employees:
2,800
IPO Date:
2007-06-01
EPS (TTM):
9.06
P/E Ratio:
-29.11
Revenue (TTM):
4.07B
Total Assets:
12.01B
Total Debt:
6.16B
Cash & Equiv:
2.41B
Rev Growth (5Y):
13.5%
EPS Growth (5Y):
-0.3%
FCF Growth (5Y):
17.8%
ROCE:
7.9%
Debt/Equity:
1.51
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-24 | $3.34 | $6.62 | -49.5% | $1.2B | $1.2B | +2.8% |
| 2025-11-05 | $8.13 | $5.95 | +36.6% | $1.1B | $1.1B | +1.3% |
| 2025-08-05 | $-8.25 | $-6.12 | -34.8% | $1.0B | $1.0B | -0.1% |
| 2025-05-06 | $1.68 | $4.51 | -62.7% | $897.8M | $1.1B | -15.7% |
| 2025-02-25 | $6.60 | $5.83 | +13.2% | $1.1B | $985.0M | +10.5% |
| 2024-11-06 | $6.61 | $5.47 | +20.8% | $1.1B | $1.1B | -0.2% |
| 2024-07-31 | $5.30 | $4.68 | +13.2% | $1.0B | $1.0B | -1.3% |
| 2024-05-01 | $2.68 | $4.14 | -35.3% | $902.0M | $954.0M | -5.4% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.07B | 3.83B | 3.66B | 3.09B | 2.36B | 2.16B | 1.89B | 1.62B | 1.49B | 1.32B | 1.17B | 872.42M |
| Net Income | 560.12M | 414.83M | (224.06M) | (328.95M) | 238.62M | 523.37M | 447.10M | 487.85M | 396.83M | 329.54M | 58.39M | 216.31M |
| EPS | 9.06 | 6.55 | -3.58 | -5.51 | 4.28 | 9.22 | 7.45 | 8.13 | 6.56 | 5.38 | 0.98 | 3.71 |
| Total Assets | 12.01B | 11.39B | 10.84B | 12.30B | 6.54B | 5.54B | 5.20B | 5.12B | 4.80B | 3.36B | 3.34B | 2.24B |
| Total Debt | 6.16B | 5.79B | 5.81B | 6.15B | 2.25B | 1.77B | 1.60B | 1.58B | 2.03B | 1.19B | 1.34B | 549.98M |
| Cash & Equivalents | 2.41B | 1.51B | 881.48M | 591.45M | 1.06B | 637.34M | 309.62M | 386.04M | 365.96M | 988.78M | 684.04M | 636.50M |
| Operating Cash Flow | 1.40B | 1.09B | 1.27B | 778.51M | 899.65M | 776.40M | 798.90M | 693.09M | 590.54M | 531.94M | 405.76M | 283.62M |
| Free Cash Flow | 1.35B | 1.07B | 773.78M | 732.98M | 520.39M | 594.07M | 667.43M | 579.14M | 408.95M | 495.99M | 166.79M | 272.34M |
| FCF per Share | 21.80 | 16.88 | 12.37 | 12.28 | 9.34 | 10.47 | 11.13 | 9.65 | 6.76 | 8.10 | 2.79 | 4.67 |
| Book Value | 4.09B | 3.74B | 3.09B | 3.97B | 3.66B | 3.11B | 2.76B | 2.71B | 1.88B | 1.60B | 1.37B | 1.30B |
| Cash & ST Investments | 2.99B | 1.63B | 881.48M | 591.45M | 2.13B | 1.08B | 824.62M | 601.03M | 425.96M | 988.78M | 684.04M | 636.50M |
| ROC Equity | 0.14 | 0.11 | -0.07 | -0.08 | 0.07 | 0.17 | 0.16 | 0.18 | 0.21 | 0.21 | 0.04 | 0.17 |